Introduction
Although O-linked carbohydrate modifications on epidermal growth factor (EGF)-like repeats have only recently been described (Harris and Spellman, 1993) , they have generated a great deal of excitement. Two kinds of O-linked structures have been reported consisting of a fucose (O-fucose) or glucose (O-glucose) attached to the EGF repeats through the hydroxyl group of serine or threonine residues. EGF repeats are small motifs with about 40 amino acids defined by 6 conserved cysteines forming three disulfide bonds (Campbell and Bork, 1993) . They are well known as players in proteinprotein interactions, such as receptor-ligand binding. Recent work in a number of laboratories has demonstrated that such receptor-ligand interactions can be affected by the alterations in the O-linked carbohydrate modifications on EGF repeats. For instance, Fringe is known to be an O-fucose-specific β1,3-N-acetylglucosaminyltransferase capable of altering Notch signal transduction by addition of GlcNAc residues to O-fucose modifications on the EGF repeats of Notch (Bruckner et al., 2000; Moloney et al., 2000a) . Recently, the presence of an O-fucose on the EGF repeat of Cripto was demonstrated to be essential for Cripto to mediate Nodaldependent signaling (Schiffer et al., 2001; Yan et al., 2002) . Coimmunoprecipitation studies suggest that the O-fucose is essential for productive interaction between Cripto and Nodal (Yan et al., 2002) . O-fucose on urinary-type plasminogen activator (uPA) also appears to be required for activation of the uPA receptor (Rabbani et al., 1992) . Defucosylated EGF repeat from uPA is able to bind to the uPA receptor, but it does not induce stimulation of signaling. Each of these examples demonstrates how alterations in an O-linked carbohydrate modification on an EGF repeat can regulate a signaling event.
The O-glucose modification was originally identified on bovine blood coagulation factors VII and IX (Hase et al., 1988) . Detailed analysis demonstrated a trisaccharide form of O-glucose on bovine factor IX with the structure Xyl-α1,3-Xyl-α1,3-Glc-β1-O-Ser (Hase et al., 1990) . Similar structures were observed on human factor VII, factor IX, and protein Z (Nishimura et al., 1989) . Comparison of the sequences surrounding sites of glycosylation on these proteins led to the proposal of a putative consensus sequence for the O-glucose addition (Harris and Spellman, 1993) . The proposed consensus sequence for addition of O-glucose is C 1 -X-S-X-P-C 2 , where C 1 and C 2 are the first and second conserved cysteines of the EGF repeat, respectively, and X can be any amino acid (Harris and Spellman, 1993) . The actual number of proteins known to be modified with the O-glucose modification is limited, but the putative consensus sequence allows database searches (Table I) revealing that numerous secreted and cell surface proteins are predicted to bear O-glucose. We recently demonstrated that the putative consensus sequence is capable of accurately predicting whether a protein bears O-glucose by showing that the Notch receptor has this modification (Moloney et al., 2000b) (Table I) .
To accumulate the tools necessary to examine the biological function of O-linked modifications on EGF repeats, we identify the enzymes responsible for their addition. At least three different enzymes are necessary of the synthesis of the O-glucose trisaccharide (Figure 1) . Two of them have been previously identified: the UDP-D-xylose: β-D-glucoside α-1,3-D-xylosyltransferase (Omichi et al., 1997) and the UDP-D-xylose: α-D-xyloside α1, 3 xylosyltransferase (Minamida et al., 1996) , responsible for adding the α1,3-Xyl onto O-glucose and the α1,3-Xyl onto Xyl, respectively. In this article we report the initial identification and characterization of the UDP-glucose: protein O-glucosyltransferase activity in extracts of Chinese hamster ovary (CHO) cells, the enzyme responsible for addition of the glucose to protein. The fact that this enzyme adds a unique modification to a number of biologically interesting proteins (Table I) suggests that it may play a role in their biology.
Results

Development of an in vitro assay for the UDP-glucose: protein O-glucosyltransferase
To develop the assay, we utilized UDP-[ 3 H]glucose as the donor substrate and a bacterially expressed recombinant factor VII EGF repeat known to contain an O-glucose consensus site (Harris and Spellman, 1993) as the acceptor substrate. Extracts of CHO cells were used as the enzyme source because we knew that CHO cells synthesize proteins bearing the O-glucose modification (Moloney et al., 2000b) . After incubation of the CHO cell lysate with factor VII EGF repeat and UDP-[ 3 H]glucose, the products were separated from unincorporated radiolabel using a C18 cartridge. The O-glucosyltransferase activity showed linear dependency on the amount of lysate (Figure 2a ), factor VII EGF repeat (Figure 2b) , and UDP-glucose (Figure 2c ).
Previous studies on the protein O-fucosyltransferase (O-FucT-1) demonstrated that the EGF repeat needed to be properly folded for the enzyme to recognize the consensus site (Wang and Spellman, 1998) . To examine whether the O-glucosyltransferase also requires folded EGF repeats, the factor VII EGF repeat was denatured in urea and reduced and alkylated with dithiothreitol (DTT) and iodoacetamide. Control factor VII EGF repeat was treated with urea but not with DTT or iodoacetamide. Both were repurified by reverse-phase highperformance liquid chromatography (HPLC) (Figure 3a) , where the reduced and alkylated form migrated somewhat later, consistent with the carboxyamidomethylation. Both the denatured and native EGF repeats were analyzed as substrates in the O-glucosyltransferase assay, and only the native EGF repeat was functional (Figure 3b ). The reduced and alkylated EGF repeat did not serve as a substrate for the enzyme, even at high concentrations. These results demonstrate that the enzyme requires a properly folded EGF repeat for recognition.
Human factor VII is modified with O-glucose at serine-52 (Hase et al., 1988) . To examine whether the predicted serine on the factor VII EGF repeat was being modified, an alanine was substituted for serine-52 (S52A: C 1 -A-S-S-P-C 2 →C 1 -A-A-S-P-C 2 ). Because the adjacent amino acid is also a serine, it was also mutated to alanine (S53A: C 1 -A-S-S-P-C 2 →C 1 -A-S-A-P-C 2 ) to examine the possibility of its modification. Both the S52A and S53A mutants were expressed in Escherichia coli and purified. Because mutations in EGF repeats can result in misfolding (Wang and Spellman, 1998) and misfolded EGF repeats are not substrates (Figure 3b ), we needed an independent measure of whether the S52A and S53A mutants were properly folded. We took advantage of the fact that O-FucT-1 also requires properly folded EGF repeats and that the factor VII EGF repeat contains an O-fucose glycosylation Thrombospondin Nishimura et al., 1992 Proteins containing the consensus sequence C-X-S/T-X-P-C (Omichi et al., 1997) and xylose α1,3-xylosyltransferase are shown (Minamida et al., 1996) .
site (Harris and Spellman, 1993) . Both the S52A and S53A mutants were essentially equivalent to wild type as a substrate for O-FucT-1 (Figure 3c ), indicating that the mutant EGF repeats were properly folded. Analysis of the same mutant in the O-glucosyltransferase assay showed no activity for the S52A mutant, whereas the S53A mutant had nearly equivalent activity to wild type ( Figure 3d ). These results demonstrate that serine-52 is essential for addition of O-glucose to factor VII EGF repeat.
Product characterization
A series of chromatographic analyses were carried out to demonstrate that the product generated in the assays consists of glucose in O-linkage to the EGF repeat. To demonstrate that the glucose is covalently associated with the EGF repeat, the product was analyzed by reverse-phase HPLC ( Figure 4a) . Furthermore, to demonstrate that the glucose was attached through an O-linkage, alkali-induced β-elimination was performed. The released sugar product from the β-elimination migrated as a monosaccharide on gel filtration chromatography ( Figure 4b ). Analysis of the monosaccharide by highperformance anion-exchange chromatography (HPAEC) revealed it to be glucitol (Figure 4c ), the expected product from β-elimination of O-glucose.
Optimization of O-glucosyltransferase assay
The O-glucosyltransferase assay was optimized for temperature, pH, and time. Product formation increased linearly with time, and, not surprisingly, the enzyme worked best at 37°C (Figure 5a, b) . Different pH values of the reaction buffer affected the enzyme activity as well (Figure 5c ), with an optimal range between pH 6 and 7.5. As with most glycosyltransferases, the O-glucosyltransferase requires metal ions for activity. In the absence of cations or in the presence of ethylenediamine tetra-acetic acid (EDTA), the O-glucosyltransferase had very little activity. Among those cations tested, manganese enhanced the activity the greatest; magnesium, calcium, and cobalt also supported some enzyme activity, whereas zinc did not (Figure 5d ). Optimal activity was achieved at a concentration of 10 mM manganese (Figure 5e ).
Distribution of O-glucosyltransferase activity
To address how widespread the O-glucose modification is in biology, we assayed extracts of cells from a variety of species and several tissues from rat for O-glucosyltransferase activity. Activity was detected in extracts of cells from all metazoans tested, although it was not detected in yeast (Figure 6a) . The activities between different cell lines varied dramatically. Lec1 (CHO), Hela (human cervical carcinoma), SF-9 (fall armyworm), and S2 (Schneider) contained moderate levels of activity, whereas HD11 cells (chicken macrophage) and NIH 3T3 (mouse embryo fibroblast) showed relatively high amounts of activity. These data suggest that this enzyme activity is found in both vertebrate and invertebrate species and that the invertebrate enzymes can recognize the glycosylation site in the EGF repeat from a vertebrate. Analysis of the rat tissue extracts (heart, liver, lung, leg muscle, kidney, spleen, and brain) suggested that this enzyme is also widely expressed in tissues (Figure 6b ), although the specific activity varies. The highest activity was found in the extract of spleen and brain, and lowest in heart and leg muscle.
Discussion
In this article, we develop an assay for and initially characterize the UDP-glucose: protein O-glucosyltransferase. Like O-FucT-1 (Wang et al., 2001; Wang and Spellman, 1998) , the O-glucosyltransferase requires a properly folded EGF repeat as an acceptor substrate. The activity requires metal ions, and optimal activity is between pH 6 and 7.5. The enzyme activity could be detected in a wide variety of tissues and metazoan species, indicating that this unusual modification is widespread in biology. Identification of this enzyme is an essential step toward a full understanding of the biological significance of the O-glucose modification.
Although the biological effect of modifying EGF repeats with O-glucose is not yet known, recent work on the O-fucose modifications of the Notch receptor (Moloney et al., 2000a) , uPA (Rabbani et al., 1992) , and Cripto (Schiffer et al., 2001; Yan et al., 2002) demonstrates that carbohydrate modifications of EGF repeats can regulate receptor-ligand interactions. If a simple O-fucose monosaccharide can alter the interaction between receptor and ligand, the more complex O-glucose modifications on the EGF repeats may have similar effects. Several observations suggest such a role for O-glucose modifications. For instance, mutation of serine-52 (the O-glucose site) to alanine in human blood coagulation factor VII results in a decrease in factor VII clotting activity by an unknown mechanism (Bjoern et al., 1991) . The conservation across species of O-glucose consensus sites on many of the proteins either known or predicted to be modified ( Table I ) strongly suggests that O-glucose plays an essential role in the function of these proteins. This is most apparent in the Notch receptor. Although Notch activity is regulated by Fringe through alteration of the O-fucose residues, Notch contains more conserved O-glucose sites than O-fucose sites (Moloney et al., 2000b) . Comparison of all Notch sequences currently in the database reveals 5 evolutionarily conserved O-fucose sites (EGF modules 3, 20, 24, 26, 31) and 12 evolutionarily conserved O-glucose sites (EGF modules 4, 10, 12, 13, 14, 16, 19, 20, 21, 25, 27, 33) .
The Notch receptor protein is extremely important for its role in numerous stages of development (Artavanis-Tsakonas et al., 1999) . In Drosophila, Notch is one of several neurogenic genes that mediate cell fate decisions during development. Targeted disruption of the Notch1 gene in mice causes embryonic lethality (Swiatek et al., 1994) . In humans, deregulation of Notch signaling results in serious diseases, such as T cell leukemias (Ellisen et al., 1991) , a cerebral arteriopathy (Joutel et al., 1996) , spondylocostal dysostosis (Bulman et al., 2000) , and Alagille syndrome (Joutel and Tournier-Lasserve, 1998; Li et al., 1997) . Notch receptor becomes activated by binding to its cell surface ligands, Delta or Serrate/Jagged (Mumm and Kopan, 2000) . Notch, Delta, and Serrate/Jagged all have numerous EGF repeats with multiple sites for O-glucose and O-fucose modifications (Moloney et al., 2000b; Panin et al., 2002) . EGF repeats 11 and 12 of Notch are necessary and sufficient for interaction with ligands (Rebay et al., 1991) . Interestingly, an evolutionarily conserved O-glucose site exists on EGF repeat 12, suggesting that the O-glucose modification at this site may play a crucial role in Notch-ligand interactions. Experiments to examine this hypothesis are currently under way.
Glucose is not often found in oligosaccharide modifications of proteins in mammalian systems. Best studied are the three α-linked glucoses attached to mannose on newly synthesized N-linked oligosaccharides. This is a transient modification that plays a role in the correct folding of glycoproteins. The glucoses are removed step by step as an indicator of proper folding (Hebert et al., 1995) . Other glucose modifications are found on glycogenin and collagen. Glycogenin, one of the two subunits of glycogen synthase complex, is an enzyme that catalyzes its own autoglucosylation, adding a α-linked glucose to itself at tyrosine 194 (Alonso et al., 1995) . The glucosylated glycogenin is the critical protein primer required for de novo glycogen synthesis. An α-linked glucose is added on to the 2′-hydroxyl of galactose during posttranslational modification of procollagen (Smith et al., 1983) . The function of the disaccharide in collagen is not clear but probably is involved in directing the correct molecular assembly of fibrils.
Only two forms of β-linked glucose modifications are known to exist on mammalian glycoproteins, including O-glucose and the disaccharide Glcβ1,3Fuc-O-Ser/Thr. Several years ago we demonstrated the presence of the Glcβ1,3Fuc disaccharide O-linked to a number of proteins in CHO cells (Moloney et al., 1997) and identified a β1,3-glucosyltransferase activity capable of adding the glucose to fucose (Moloney and Haltiwanger, 1999) . We had originally believed these disaccharides to exist on EGF repeats, because O-fucose was only known on EGF repeats at that time. A recent elegant study by Hofsteenge and co-workers (2001) using mass spectral analysis of thrombospondin-1 revealed the presence of two unusual carbohydrate modifications: C-linked mannose on several tryptophans and the O-linked disaccharide Glc-Fuc on several serine/threonine residues. This work demonstrated that Glc-Fuc disaccharides are not on EGF repeats, but instead are found on a different type of protein domain called a thrombospondin-type 1 repeat (TSR) (Adams and Tucker, 2000) . Neither the enzyme responsible for addition of O-fucose to the TSR nor the biological function of this modification is yet known.
The anomeric linkage of O-glucose was established in a single study (Hase et al., 1990) where nuclear magnetic resonance (NMR) was utilized to analyze the structure of the Oglucose modification on bovine factor IX. No other data on the anomeric linkage of O-glucose exists. In particular, no successful enzymatic cleavage of O-glucose from protein has been reported. We have been unsuccessful in several attempts to remove O-glucose from factor VII EGF repeat or glycopeptides derived from glucosylated EGF repeat using either α-or β-glucosidases, suggesting that this linkage is uniquely resistant to enzymatic digestion. Although the O-glucose on factor VII EGF repeat is likely to be β-linked, definitive demonstration of the linkage awaits production of sufficient product to pursue NMR analysis.
Unusual carbohydrate modifications are often related to a specific biological event (Varki, 1993) . For example, mannose 6-phosphate targets lysosomal enzymes to lysosomes (Kornfeld, 1990) , sialyl Lewis x helps recruit leukocytes to sites of inflammation (Zak et al., 2000) , and polysialic acid modulates neural cell adhesion molecule interactions during neuronal development (Acheson et al., 1991) . The recent work demonstrating that O-fucose modifications on the EGF repeats of Notch, uPA, and Cripto play a role in signaling events provide other clear examples of a rare form of glycosylation performing a specific biological function. The O-glucose modifications of EGF repeats are another unusual form of glycosylation that we predict will have an equally specific role in the biology of the proteins it modifies. We have initiated attempts to purify the O-glucosyltransferase by using a combination of conventional and affinity chromatography. Purifying and cloning this enzyme will allow us to develop the tools necessary to study this unique modification.
Materials and methods
Materials
UDP-β-D-Glucose was purchased from Sigma. UDP-[6-3 H]glucose (60 Ci/mmol) was purchased from American Radiolabeled Chemicals (St. Louis, MO). Human factor VII EGF was both kindly provided by Dr. Yang Wang (Genentech, San Francisco, CA) and synthesized as described later. The CHO Lec1 cell line was developed by Pamela Stanley (Stanley and Siminovitch, 1977) . Lec1, Hela, SF-9, S2, and NIH3T3 cells were from American Type Culture Collection (Rockville, MD). HD11 cells (Beug et al., 1979) were kindly provided by Dr. Michael Hayman (Department of Microbiology, SUNY Stony Brook). Alditol sugar standards were prepared by reductions of the corresponding sugar with sodium borohydride as described elsewhere (Haltiwanger et al., 1990) . C18 cartridges were obtained from Waters Associated (Milford, MA). Reverse-phase C18 HPLC columns (4.6 × 250 mm; Dyanamax) were purchased from Rainin (Woburn, MA). Protease inhibitor cocktails I and II were prepared as described elsewhere (Holt and Hart, 1986) . All other reagents were of the highest quality available.
Preparation of cell lysates and rat tissues
All mammalian cells were grown in 100-mm dishes in a humidified 37°C incubator with 5% CO 2 . Lec1 cells were grown in αMEM medium (Mediatech, Herndon, VA) supplemented with 10% fetal bovine serum (HyClone, Logan, UT). Hela and NIH3T3 cells were grown in Dulbecco's modified Eagle's medium (Gibco, Life Technologies, Rockville, MD) supplemented with 10% fetal bovine serum. SF-9 cells were grown at room temperature in Grace's insect medium (Gibco, Life Technologies) supplemented with 10% fetal bovine serum. S2 cells were also grown at room temperature in Shields and Sang M3 insect medium (Sigma) with 10% fetal bovine serum. Cells were collected by scraping and washed three times with Tris-buffered saline (10 mM Tris-HCl, pH 7.5, 0.15 M NaCl). Yeast cell pellets were generously provided by Rolf Sternglanz (Department of Biochemistry and Cell Biology, SUNY Stony Brook). Cell pellets were lysed on ice in Tris-buffered saline with 1% (w/v) Nonidet P-40 and protease inhibitor cocktails I and II (yeast cell pellets were lysed by vortexing with glass beads) (Sutton et al., 1991) . Cell debris was pelleted by centrifugation (14,000 rpm, 10 min). The supernatants were aliquoted, frozen in liquid nitrogen, and stored at -80°C. Extracts of rat tissues were prepared as described (Moloney and Haltiwanger, 1999) .
Production of recombinant factor VII EGF1 repeat and
O-glucose site mutants in E. coli DNA sequences encoding human factor VII EGF1 domain were cloned into a pET20b (+) vector (Novagen, Madison, WI) using BamHI (Invitrogen, Carlsbad, CA) and XhoI (Invitrogen) restriction sites with primers containing BamHI and XhoI restriction sites on the 5′-and 3′-ends, respectively (5′-CCGAAGGATCCGGCAAGT GATGGTGACCAG-3′, and 5′-CTGCCCTCGAGCCCGTCATCCTTGTG-3′). A plasmid encoding EGF1 from human factor VII (generously provided by Yang Wang et al., 1996) was used as template. Polymerase chain reaction was carried out for 30 cycles with the following conditions: denaturing at 95°C for 0.5 min; annealing at 65°C for 1 min; elongating at 72°C for 1 min. Serine-52 was changed to Ala (S52A) using the Strategene Quik Change Site-Directed Mutagenesis Protocol, with the primers 5′-GGTGACCAGTGT GCCGCGAGTCCATGCC-AG-3′ and 5′-CTGGCATGGACTCGCGGCACACTGGTCA CC-3′. Serine-53 was changed to Ala (S53A) using the primers 5′-GACCAGTGTGCCTCGGCTCCATGCCAGAATGGT-3′ and 5′-ACCATTCTGGCATGGAGCCGAGGCACACTGG-TC-3′. All constructs were sequenced prior to further study.
To produce protein, transformed bacteria BL21 (DE3) were grown to an absorbency of 0.6 at 600 nm in the presence of 100 mg/L ampicillin, 37°C, and induced with 1 mM isopropyl-β-thiogalactopyranoside overnight at 25°C. Cells were harvested by centrifugation, and periplasmic shock was performed according to the Qiagen manual. The shockate was dialyzed extensively against dialysis buffer (50 mM Tris-HCl pH 8.0, 10 mM imidazole) at 4°C, and purified using Qiagen Ni-NTA resin. The resin was washed with the dialysis buffer, and the protein was eluted with 50 mM Tris-HCl, pH 8.0, 100 mM imidazole.
To identify properly folded EGF repeat, a portion of the purified EGF repeat was radiolabeled using baculovirus overexpressed O-FucT-1 and GDP-[ 3 H]fucose (as described in Wang et al., 2001; Wang and Spellman, 1998) . Reverse-phase HPLC was performed to separate the properly folded EGF repeats from misfolded variants as described later, and the properly folded form was identified by the presence of [ 3 H]fucose. The remainder of the EGF repeat was then purified in the same manner on a preparative scale. The final concentration of factor VII EGF1 was determined by a BCA assay (Pierce). The factor VII EGF1 repeats containing the S52A and S53A mutants were expressed and purified in the same manner.
O-Glucosyltransferase assay
The reaction mixture (50 µl final volume) contained 50 mM HEPES, pH 7.0, 10 mM MnCl 2 , 4.8 µM recombinant human factor VII EGF-1 repeat, 0.2 µM UDP-[ 3 H]glucose, 2.8 µM UDP-glucose, and 10-20 µg cellular protein. The reaction was incubated at 37°C for 20 min and stopped by addition of 450 µl 50 mM EDTA, pH 8. The EGF repeat was separated from unincorporated radioactivity on C18 cartridges using a vacuum manifold. The sample was loaded onto a C18 cartridge (100 mg). The cartridge was washed with 8 ml water, and the EGF repeat was eluted with 1.5 ml 80% methanol. Incorporation of [ 3 H]glucose into the EGF repeat was determined by scintillation counting of the eluate. Reactions without EGF repeat were used as background control.
Reduction and alkylation of EGF repeat
Two aliquots of recombinant factor VII EGF repeat (4.8 nmole each) were dried in a Speed Vac. Both samples were dissolved in 25 µl 0.4 M NH 4 HCO 3 containing 8 M urea (final pH between 7.5 and 8.5). Water (10 µl) was added to one sample as control. The other sample was reduced by adding 5 µl 45 mM DTT and incubating at 50°C for 15 min. After cooling to room temperature, the sample was alkylated by adding 5 µl 200 mM iodoacetamide and incubating at room temperature for another 15 min. Both the control EGF repeat and the reduced and alkylated EGF repeat were purified on reversephase HPLC as described.
Reverse-phase HPLC purification
Reverse-phase HPLC was performed on a 250 × 4.6 mm Dynamax C18 column using a 30-min linear gradient from 0% to 80% acetonitrile in 0.1% trifluoracetic acid at 1 ml/min. Peptide was detected at 214 nm. Fractions (1 min) were collected as necessary.
Product analysis by gel filtration chromatography and HPAEC
Radiolabeled product in the eluant from the glucosyltransferase assay was dried in a Speed-Vac. Alkali-induced β-elimination, gel filtration on Superdex column, and HPAEC analysis of the products on a Carbopac MA-1 column (Dionex, Sunnyvale, CA) were all done as described (Moloney et al., 1997 (Moloney et al., , 2000b 
